March 2014 in “Journal of The American Academy of Dermatology” Azathioprine may be an effective treatment for severe hair loss.
January 2026 in “Annals of Dermatology” Alitretinoin may help treat mild to moderate alopecia areata.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
May 2025 in “International Journal of Science and Research (IJSR)” Stopping azathioprine led to full hair regrowth and recovery in 2.5 months.
March 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
54 citations
,
May 2019 in “Multiple Sclerosis and Related Disorders” Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.
January 2026 in “Forum Dermatologicum” JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
13 citations
,
June 2010 in “Journal of dermatological treatment” Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
21 citations
,
December 2014 in “Clinics in dermatology” Squaric acid dibutylester effectively treats alopecia areata.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
December 2024 in “Drug Discoveries & Therapeutics” Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
4 citations
,
June 2025 in “Frontiers in Immunology” BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
22 citations
,
October 2007 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Combining isotretinoin and dapsone effectively treated a challenging scalp condition.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
11 citations
,
May 2010 in “Journal of the South African Veterinary Association” Mycophenolate mofetil helped reduce steroid use in treating a dog's autoimmune skin disease.
136 citations
,
April 2010 in “British Journal of Dermatology” Acitretin is effective for severe skin conditions but has significant side effects and requires careful monitoring.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.